EICHORCondition: HIV Infections · Sponsor: ViiV Healthcare
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Birmingham, Alabama, United States | — |
| GSK Investigational Site | Bakersfield, California, United States | — |
| GSK Investigational Site | Los Angeles, California, United States | — |
| GSK Investigational Site | Los Angeles, California, United States | — |
| GSK Investigational Site | Palm Springs, California, United States | — |
| GSK Investigational Site | Sacramento, California, United States | — |
| GSK Investigational Site | San Francisco, California, United States | — |
| GSK Investigational Site | New Haven, Connecticut, United States | — |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | — |
| GSK Investigational Site | Washington D.C., District of Columbia, United States | — |
| GSK Investigational Site | Fort Lauderdale, Florida, United States | — |
| GSK Investigational Site | Ft. Pierce, Florida, United States | — |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996471